MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aandelen Lijst・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Gesloten

3.95 -1

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.87

Max

3.95

Belangrijke statistieken
By Trading Economics
Inkomsten	466K -27M
Verkoop	2M 15M
Winstmarge	-178.834
Werknemers	141
EBITDA	-2M -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+270.45% upside

Dividenden
By Dow Jones
Volgende Winsten	4 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.1M 231M
Vorige openingsprijs	4.95
Vorige sluitingsprijs	3.95

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

3.17 / 3.4644 Steun & Weerstand

Voyager Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2026, 04:27 UTC

Belangrijke Nieuwsgebeurtenissen

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5 apr 2026, 23:55 UTC

Marktinformatie

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5 apr 2026, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 apr 2026, 23:42 UTC

Marktinformatie

China's Consumer Inflation Likely Eased in March -- Market Talk

5 apr 2026, 23:38 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5 apr 2026, 12:57 UTC

Belangrijke Nieuwsgebeurtenissen

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Marktinformatie

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Marktinformatie

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisities, Fusies, Overnames

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Winsten

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Belangrijke Nieuwsgebeurtenissen

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisities, Fusies, Overnames

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Marktinformatie

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Marktinformatie

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Voyager Therapeutics Inc Prognose

Koersdoel

By TipRanks

270.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.67 USD 270.45%

Hoogste 25 USD

Laagste 8 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Voyager Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Voyager Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.17 / 3.4644Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.